Arbele has developed proprietary technology platforms to generate new Immunotherapeutics possessing multiple anti-tumor mechanisms for greater efficacy. 
Cutting-edge proprietary technologies to address solid tumors:

AI-CAR/NK cell therapeutic platform

TriAx multipspecific antibody platform 

pAC01 single-vector system for trispecific biomanufacturing in CHO cells

CA-17 diagnostics (for tissue and liquid biopsies) – companion and POC tests

error: Content is protected !!